Detection of recent HIV-1 infection using a new limiting-antigen avidity assay: Potential for HIV-1 incidence estimates and avidity maturation studies

PLoS ONE

Volumn 7, Issue 3, 2012, Pages

  Duong, Yen T ^a   Qiu, Maofeng ^a,b   De, Anindya K ^a   Jackson, Keisha ^a   Dobbs, Trudy ^a   Kim, Andrea A ^a   Nkengasong, John N ^a   Parekh, Bharat S ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; AVIDITY INDEX ENZYME IMMUNOASSAY; BED ENZYME IMMUNOASSAY; CONTROLLED STUDY; ENZYME IMMUNOASSAY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INTERMETHOD COMPARISON; LIMITING ANTIGEN AVIDITY ENZYME IMMUNOASSAY; MAJOR CLINICAL STUDY; MIXED INFECTION; NONHUMAN; REPRODUCIBILITY; SEROCONVERSION; TUBERCULOSIS; VIRUS DETECTION; WESTERN BLOTTING; ANTIBODY AFFINITY; BLOOD; GROWTH, DEVELOPMENT AND AGING; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; LONGITUDINAL STUDY; METHODOLOGY; SENSITIVITY AND SPECIFICITY; VIRUS LOAD;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ANTIBODY AFFINITY; HIV ANTIBODIES; HIV ANTIGENS; HIV INFECTIONS; HIV SEROPOSITIVITY; HIV-1; HUMANS; IMMUNOENZYME TECHNIQUES; LONGITUDINAL STUDIES; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; VIRAL LOAD;

EID: 84858994632     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0033328     Document Type: Article

References (44)

1. Karim QA, Kharsany AB, Frohlich JA, Werner L, Mashego M, et al. (2011) Stabilizing HIV prevalence masks high HIV incidence rates amongst rural and urban women in KwaZulu-Natal, South Africa. Int J Epidemiol 40: 922-930.
2. Mastro TD, Kim AA, Hallett T, Rehle T, Welte A, et al. (2010) Estimating HIV Incidence in Populations Using Tests for Recent Infection: Issues, Challenges and the Way Forward. J HIV AIDS Surveill Epidemiol 2: 1-14.
3. Busch MP, Pilcher CD, Mastro TD, Kaldor J, Vercauteren G, et al. (2010) Beyond detuning: 10 years of progress and new challenges in the development and application of assays for HIV incidence estimation. AIDS 24: 2763-2771.
4. Janssen RS, Satten GA, Stramer SL, Rawal BD, O'Brien TR, et al. (1998) New testing strategy to detect early HIV-1 infection for use in incidence estimates and for clinical and prevention purposes. [erratum appears in JAMA 1999 May 26;281(20):1893]. JAMA 280: 42-48.
5. Parekh BS, Pau CP, Kennedy MS, Dobbs TL, McDougal JS, (2001) Assessment of antibody assays for identifying and distinguishing recent from long-term HIV type 1 infection. AIDS Research & Human Retroviruses 17: 137-146.
6. Parekh BS, Kennedy MS, Dobbs T, Pau CP, Byers R, et al. (2002) Quantitative detection of increasing HIV type 1 antibodies after seroconversion: a simple assay for detecting recent HIV infection and estimating incidence. AIDS Research & Human Retroviruses 18: 295-307.
7. Suligoi B, Galli C, Massi M, Di Sora F, Sciandra M, et al. (2002) Precision and accuracy of a procedure for detecting recent human immunodeficiency virus infections by calculating the antibody avidity index by an automated immunoassay-based method. Journal of Clinical Microbiology 40: 4015-4020.
8. Kothe D, Byers RH, Caudill SP, Satten GA, Janssen RS, et al. (2003) Performance characteristics of a new less sensitive HIV-1 enzyme immunoassay for use in estimating HIV seroincidence. Journal of Acquired Immune Deficiency Syndromes: JAIDS 33: 625-634.
9. Rawal BD, Degula A, Lebedeva L, Janssen RS, Hecht FM, et al. (2003) Development of a new less-sensitive enzyme immunoassay for detection of early HIV-1 infection. Journal of Acquired Immune Deficiency Syndromes: JAIDS 33: 349-355.
10. Suligoi B, Massi M, Galli C, Sciandra M, Di Sora F, et al. (2003) Identifying recent HIV infections using the avidity index and an automated enzyme immunoassay. Journal of Acquired Immune Deficiency Syndromes: JAIDS 32: 424-428.
11. Barin F, Meyer L, Lancar R, Deveau C, Gharib M, et al. (2005) Development and validation of an immunoassay for identification of recent human immunodeficiency virus type 1 infections and its use on dried serum spots. Journal of Clinical Microbiology 43: 4441-4447.
12. Brookmeyer R, Quinn TC, (1995) Estimation of Current Human Immunodeficiency Virus Incidence Rates from a Cross-Sectional Survey Using Early Diagnostic Tests. American J of Epidemiology 141: 166-172.
13. Dobbs T, Kennedy S, Pau CP, McDougal JS, Parekh BS, (2004) Performance characteristics of the immunoglobulin G-capture BED-enzyme immunoassay, an assay to detect recent human immunodeficiency virus type 1 seroconversion. Journal of Clinical Microbiology 42: 2623-2628.
14. Hu DJ, Vanichseni S, Mock PA, Young NL, Dobbs T, et al. (2003) HIV type 1 incidence estimates by detection of recent infection from a cross-sectional sampling of injection drug users in Bangkok: use of the IgG capture BED enzyme immunoassay. AIDS Research & Human Retroviruses 19: 727-730.
15. Nesheim S, Parekh B, Sullivan K, Bulterys M, Dobbs T, et al. (2005) Temporal trends in HIV Type 1 incidence among inner-city childbearing women in Atlanta: use of the IgG-capture BED-enzyme immunoassay. AIDS Research & Human Retroviruses 21: 537-544.
16. Saphonn V, Parekh BS, Dobbs T, Mean C, Leng HB, Hena S, Detels R, (2005) Trends of HIV seroincidence among HIV sentinel surveillance groups in Cambodia, 1999-2002. Journal of Acquired Immune Deficiency Syndromes: JAIDS 39: 587-592.
17. Rehle T, Shisana O, Pillay V, Zuma K, Puren A, et al. (2007) National HIV incidence measures-new insights into the South African epidemic.[see comment]. South African Medical Journal Suid-Afrikaanse Tydskrif Vir Geneeskunde 97: 194-199.
18. Hall HI, Song R, Rhodes P, Prejean J, An Q, et al. (2008) Estimation of HIV incidence in the United States.[see comment]. JAMA 300: 520-529.
19. Price M, Wallis CL, Lakhi S, Karita E, Kamali A, Anzala O, Sanders EJ, Bekker LG, Twesigye R, Hunter E, Kaleebu P, Kayitenkore K, Allen S, Ruzagira E, Mwangome M, Mutua G, Amornkul PN, Stevens G, Pond SLK, Schaefer M, Papathanasopoulos MA, Stevens W, Gilmour J, (2011) Transmitted HIV type 1 drug resistance among individuals with recent HIV infection in east and southern Africa. AIDS Research & Human Retroviruses 27: 5-12.
20. Parekh BS, Hu DJ, Vanichseni S, Satten GA, Candal D, et al. (2001) Evaluation of a sensitive/less-sensitive testing algorithm using the 3A11-LS assay for detecting recent HIV seroconversion, among individuals with HIV-1 subtype B or E infection in Thailand. AIDS Research & Human Retroviruses 17: 453-458.
21. Young CL, Hu DJ, Byers R, Vanichseni S, Young NL, et al. (2003) Evaluation of a sensitive/less sensitive testing algorithm using the bioMerieux Vironostika-LS assay for detecting recent HIV-1 subtype B′ or E infection in Thailand. AIDS Research & Human Retroviruses 19: 481-486.
22. Parekh BS, Hanson DL, Hargrove J, Branson B, Green T, et al. (2011) Determination of mean recency period for estimation of HIV type 1 Incidence with the BED-capture EIA in persons infected with diverse subtypes. AIDS Res Hum Retroviruses 27: 265-273.
23. Thomas HI, Wilson S, O'Toole CM, Lister CM, Saeed AM, et al. (1996) Differential maturation of avidity of IgG antibodies to gp41, p24 and p17 following infection with HIV-1. Clinical & Experimental Immunology 103: 185-191.
24. Chawla A, Murphy G, Donnelly C, Booth CL, Johnson M, et al. (2007) Human immunodeficiency virus (HIV) antibody avidity testing to identify recent infection in newly diagnosed HIV type 1 (HIV-1)-seropositive persons infected with diverse HIV-1 subtypes. Journal of Clinical Microbiology 45: 415-420.
25. Wei X, Liu X, Dobbs T, Kuehl D, Nkengasong JN, Hu DJ, Parekh BS, (2010) Development of Two Avidity Based Assays to Detect Recent HIV-1 Seroconversion Using a Multi-subtype gp41 Recombinant Protein. AIDS Research & Human Retroviruses 26: 61-71.
26. Smith D, Warren DL, Vlahov D, Schuman P, Stein MD, Greenberg BL, Holmberg SD, for the Human Immunodeficiency Virus Epidemiology Research Study Group (1997) Design and baseline participant characteristics of the Human Immunodeficiency Virus Epidemiology Research (HER) Study: a prospective cohort study of human immunodeficiency virus infection in US women. Am J epidemiology 146: 459-469.
27. Parekh B, Wei X, Dobbs T, Kuehl D, Hu D, Nkengasong J, Development of a Limiting-antigen Avidity-based Enzyme Immunoassay Using a Chimeric Recombinant gp41 Protein to Detect Recent HIV-1 Infection 2007 February 25-28; Los Angeles.
28. Ying S, Gordon J, Se HK, Inc. SI, editor Analyzing Interval-Censored Survival Data with SAS® Software. 2010; Cary, NC.
29. Rehle T, Hallett T, Shisana O, Pillay V, Zuma K, et al. (2010) A Decline in New HIV Infections in South Africa: Estimating HIV Incidence from Three National HIV Surveys in 2002, 2005 and 2008. PLoS One/Public Library of Science 5: e11094 doi:11010.11371/journal.pone.0011094.
30. UNAIDS (2010) UNAIDS Report on the global AIDS epidemic 2010. Joint United Nations Programme on HIV/AIDS (UNAIDS).
31. Guy R, Gold J, Calleja JMG, Kim AA, Parekh B, et al. (2009) Accuracy of serological assays for detection of recent infection with HIV and estimation of population incidence: a systematic review. The Lancet Infectious Diseases 9: 747-759.
32. Barnighausen T, McWalter TA, Rosner Z, Newell ML, Welte A, (2010) HIV incidence estimation using the BED capture enzyme immunoassay: systematic review and sensitivity analysis. Epidemiology 21: 685-697.
33. Kim AA, McDougal JS, Hargrove J, Rehle T, Pillay-Van Wyk V, et al. (2010) Evaluating the BED capture enzyme immunoassay to estimate HIV incidence among adults in three countries in sub-Saharan Africa. AIDS Res Hum Retroviruses 26: 1051-1061.
34. Dobbs T, Liu X, Anderson R, Nkengasong J, Parekh BS, (2011) A comprehensive evaluation of the proficiency testing program for the HIV-1 BED incidence assay. J Clin Microbiol In press.
35. Hargrove JW, Humphrey JH, Mutasa K, Parekh BS, McDougal JS, et al. (2008) Improved HIV-1 incidence estimates using the BED capture enzyme immunoassay. AIDS 22: 511-518.
36. Hargrove JW, (2009) BED estimates of HIV incidence must be adjusted. AIDS 23: 2061-2062; author reply 2066-2068.
37. UNAIDS (2006) UNAIDS Reference Group on estimates, modelling and projections-statement on the use of the BED assay for the estimation of HIV-1 incidence for surveillance or epidemic monitoring. Wkly Epidemiol Rec 81: 40.
38. UNAIDS/WHO (2011) When and how to use assays for recent infection to estimate HIV incidence at a population level. URL: http://www.who.int/diagnostics_laboratory/110906_guidance_hiv_incidence.pdf.
39. Novitsky V, Wang R, Kebaabetswe L, Greenwald J, Rossenkhan R, et al. (2009) Better control of early viral replication is associated with slower rate of elicited antiviral antibodies in the detuned enzyme immunoassay during primary HIV-1C infection. Journal of Acquired Immune Deficiency Syndromes: JAIDS 52: 265-272.
40. Laeyendecker O, Rothman RE, Henson C, Horne BJ, Ketlogetswe KS, et al. (2008) The effect of viral suppression on cross-sectional incidence testing in the johns hopkins hospital emergency department. Journal of Acquired Immune Deficiency Syndromes: JAIDS 48: 211-215.
41. Hladik W, Olara D, Mermin J, Moore D, Were W, et al. (2011) Effect of CD4(+) T Cell Count and Antiretroviral Treatment on Two Serological HIV Incidence Assays. AIDS Res Hum Retroviruses.
42. Vainea M, Wanga S, Hacketta A, Arthosb J, Lua S, (2010) Antibody responses elicited through homologous or heterologous prime-boost DNA and protein vaccinations differ in functional activity and avidity. Vaccine 28: 2999-3007.
43. Klein J, Bjorkman P, (2010) Few and Far Between: How HIV May Be Evading Antibody Avidity. PLoS Pathogen 6: 1-6.
44. Wilson KM, Johnson EI, Croom HA, Richards KM, Doughty L, et al. (2004) Incidence immunoassay for distinguishing recent from established HIV-1 infection in therapy-naive populations. AIDS 18: 2253-2259.